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lem remains unsolved in the trachea, as in most organs
in which transplantation has been clinically performed.
A long-term period of preservation is one of the meth-
ods to help solve this problem. However, such preser-
vation is generally difficult under usual temperature
conditions. 
Cryopreservation of the trachea has been experimen-
tally attempted, probably because of its simple struc-
ture,1,2 and that of cardiac valves and cartilage has
already been practiced in a clinical setting for the same
reasons.3,4 The effect of cryopreservation on tracheal
grafts remains to be elucidated. We first investigated the
effect of cryopreservation on tracheal isografts in this
study. In clinical use, an easy and cheap system of cryo-
preservation is desirable. We thus assessed the maximal
period of cryopreservation for viable grafts when a sim-
ple and gradual freezing vessel was used in this study.
We used isografts to avoid the immunologic complexi-
ty of allografts. A prolonged period and an easy system
Although transplantation of the trachea is consideredto be the preferred method for the reconstruction of
extensive tracheal defects in the future, the deficit of
donor trachea will remain a major obstacle. This prob-
Objective: The maximal period of cryopreservation for the trachea is still
unsolved. We assessed the maximal period of cryopreservation using the
Bicell biofreezing vessel as an easy and cheap slow-freezing instrument
for viable tracheal grafts in 95 rats. Methods: Each isograft was harvest-
ed from 17 donor rats, immersed in the preservative solution, and stored
in a Bicell device in a deep freezer at –80°C. The tracheal isografts were
then randomly assigned to 9 groups according to cryopreservation peri-
ods ranging from 0 to 12 months. Included in the 9 groups were 2 sub-
groups (n = 6 per subgroup) that were observed immediately after being
thawed and 1 month after heterotopic transplantation into the omentum
after being thawed. Four subgroups (n = 6 per subgroup) were added
according to the cryopreservation period for 1, 3, 6, and 12 months to
evaluate the graft morphology 3 months after being thawed and trans-
planted heterotopically. Results: A prolonged period of cryopreservation
had a degenerative effect on both the epithelium and cartilage. One
month after transplantation, degeneration was more pronounced in the
cartilage than in the epithelium, as characterized by the viable chon-
drocyte ratio and the epithelial score of isografts undergoing cryo-
preservation for more than 9 months. Three months after transplanta-
tion, the morphology of the epithelium and cartilage in isografts
undergoing cryopreservation for less than 3 months was better pre-
served, whereas the morphology of both deteriorated in isografts under-
going cryopreservation for more than 6 months. Conclusions: We con-
clude that the permissible period of cryopreservation to maintain
tracheal isograft viability in this simple system using a Bicell biofreez-
ing vessel is 3 months. (J Thorac Cardiovasc Surg 1999;117:1070-6)
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of cryopreservation could help us to resolve the short-
age of donors.
Materials and methods
Animals and anesthesia. The heterotopic tracheal trans-
plant model with omental wrapping was used with a tech-
nique modified for rats.5,6 Ninety-five male Lewis rats
between 10 and 12 weeks of age and weighing approximate-
ly 250 to 300 g were premedicated with anesthetic ether. The
animals were placed in the supine position and anesthetized
with sodium pentobarbital (10 mg/kg given intraperitoneal-
ly). Under spontaneous ventilation without an endotracheal
tube, either harvesting or transplantation was performed. All
animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” published by
the National Institutes of Health (NIH Publication No. 85-23,
revised 1985).
Harvesting and cryopreservation. A total of 132 tracheal
segments consisting of 3 rings were harvested from 17 donor
rats. Through a midline cervical to sternal incision, the
whole trachea was identified and excised in continuity. The
wound was closed in the usual fashion. The harvested tra-
chea was trimmed off in 3-ring segments. Twelve tracheal
segments served as controls and are termed “fresh isografts.”
The remaining 120 segments were then immediately stored
in a plastic sterile tube filled with the freezing solution. The
preservative solution in which the grafts were immersed con-
tained a balanced buffered salt solution with L-glutamine
(RPMI-1640 medium; JRM Biosciences, Lenexa, Kan) with
a final concentration of 20% fetal calf serum and 10%
dimethyl sulfoxide (DMSO) as a cryoprotectant. The plastic
tube containing the specimen was then stored in a Bicell
biofreezing vessel (Nihon Freezer Co, Ltd, Tokyo, Japan)
and subsequently stored in a deep freezer at –80°C. The
Bicell device has the ability to cool down at a rate of approx-
imately 1°C per minute in a deep freezer until reaching
–80°C.
Experimental design and grafting. Cryopreserved iso-
grafts were thawed in an incubator for 15 minutes at 37°C for
grafting. The tracheal isografts were randomly assigned to 9
groups according to the cryopreservation period for 0 to 12
months (0, 0.25 = 1 week; 0.5 = 2 weeks; 1, 2, 3, 6, 9, and 12
months), including 2 subgroups (n = 6 per subgroup): sub-
group a, observation immediately after the tissue was thawed;
subgroup b, observation 1 month after the tissue was thawed
and transplanted heterotopically. Four subgroups (n = 6 per
subgroup) were added according to the cryopreservation peri-
od, that is, for 1, 3, 6, and 12 months, and were evaluated as
subgroup c 3 months after heterotopic transplantation after
thawing (Table I). The isografts in subgroups b and c of
groups 1 to 9 were stented over a silicone rod 1.35 mm in
diameter (ATOM, Inc, Tokyo, Japan) and then were hetero-
topically implanted into the omentum of 78 recipient rats. A
silicone rod was used to prevent the omentum from intruding
into the graft. The recipient animals were placed in the supine
position. Through a small upper midline laparotomy, the
greater omentum was delivered into the wound. The anterior
layer of the omentum was opened, and the tracheal transplant
was completely enveloped. The omentum and the enclosed
transplant were then returned to the peritoneal cavity, and the
wound was closed. After 1 or 3 months, a second laparotomy
was performed in 9 groups to retrieve the transplants for
histopathologic analysis.
Histopathologic assessment. All tissue specimens were
fixed in 10% formalin. Microscopic slides were made from
cross sections of the midportion of the tracheal segment and
adherent omentum and were stained routinely with hema-
toxylin and eosin. Thereafter, all specimens were examined
with a light microscope. We attempted to quantify the viabil-
ity of the heterotopically grafted trachea by subjectively eval-
uating the epithelial structure and objectively calculating the
ratio of chondrocytes possessing a viable nucleus in the car-
tilage. The assessment was performed in a blinded fashion.
Epithelial viability. Epithelial viability was evaluated
according to the following grading system: 0, no epithelium;
1, a single layer of nonciliated epithelium; 2, multiple layers
of nonciliated epithelium; and 3, normal mucociliary epithe-
lium. The epithelium of the grafts was assessed as a ratio of
the epithelial score on a microscopic slide.7,8
Cartilage viability. The ratio of chondrocytes possessing
viable nuclei in the cartilage of each transplant was calculat-
ed after carefully counting the number of all chondrocytes in
each high-power field on a microscopic slide. A viable chon-
drocyte nucleus was regarded as richly stained and possess-
ing a clear nuclear membrane.
Table I. Experimental design
Groups 
(n = 6 Cryopreservation Heterotopic Transplantation 
per group) period (mo) transplantation period (mo)
1a 0 – 0
1b 0 + 1
2a 0.25 – 0
2b 0.25 + 1
3a 0.5 – 0
3b 0.5 + 1
4a 1 – 0
4b 1 + 1
4c 1 + 3
5a 2 – 0
5b 2 + 1
6a 3 – 0
6b 3 + 1
6c 3 + 3
7a 6 – 0
7b 6 + 1
7c 6 + 3
8a 9 – 0
8b 9 + 1
9a 12 – 0
9b 12 + 1
9c 12 + 3
–, Not done; +, done; 0.25 months = 1 week; 0.5 months = 2 weeks.
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Statistical analysis. All data were presented as the mean ±
standard deviation of the mean. A statistical analysis was per-
formed with the paired Student t test.
Results
Gross appearance. The omentum was wrapped
firmly around the tracheal isografts in all rats. Grossly,
all free tracheal isografts appeared normal and also pre-
served their luminal rigidity.
Histopathology. Isografts in subgroups a and b in
groups 1 to 9, according to the period of cryopreserva-
tion, showed the histologic characteristics of the epitheli-
um and cartilage to worsen gradually, but not to a critical
extent. The free isografts had little infiltration of inflam-
matory cells or submucosal thickening by fibrous tissue.
Epithelial viability. The epithelium of the isografts
immediately after being thawed was partially denuded.
The remaining epithelium showed degeneration and
was separated from the submucosal tissue. The epithe-
lial score of the cryopreserved isografts immediately
after thawing, irrespective of the period of cryopreser-
vation, was significantly worse than that of the fresh
isografts (Fig 1, subgroup a). In subgroup b, likewise,
the score of the isografts undergoing cryopreservation
for 0.5 to 12 months was significantly worse than that
of the fresh isografts (Fig 1, subgroup b). However,
some isografts that underwent the same treatment after
cryopreservation for less than 9 months showed that the
epithelium was often regenerated at the membranous
portion and had partially normal mucociliary epitheli-
um. The epithelial score of the isografts undergoing
heterotopic transplantation after being thawed showed
a little better trend than that of the isografts immedi-
ately after being thawed for each period of cryopreser-
vation except for 12 months (Fig 1). The tracheal iso-
grafts of subgroup c showed 2 types of epithelial
morphology, including regeneration and degeneration.
In the epithelial score of those isografts, significant dif-
ferences were observed between 1 or 3 and 6 or 12
months of cryopreservation (Table II). Some isografts
cryopreserved for 1 or 3 months demonstrated more
mucociliary or multilayer epithelium in subgroup c
than in subgroup b (Fig 2, A and B). In contrast, the iso-
grafts cryopreserved for 6 or 12 months tended to show
an exacerbated score by means of a prolonged period of
transplantation treatment (Table II), and the isografts of
subgroup c had a partially single or multilayer noncili-
ated epithelium.
Cartilage viability. The cartilage viability of the iso-
grafts showed an exacerbating trend as the period of
cryopreservation increased. Immediately after the tis-
sue was thawed, the ratio of viable chondrocytes in the
isografts cryopreserved for more than 1 month was sig-
nificantly less than that of the fresh isografts (Fig 3,
subgroup a). Likewise, the ratio of viable chondrocytes
of the isografts undergoing a heterotopic transplanta-
tion after cryopreservation for 2 to 12 months was sig-
nificantly less than that of fresh isografts (Fig 3, sub-
group b). Especially in the isografts cryopreserved for
more than 9 months, the ratio of viable chondrocytes of
isografts in subgroup b was significantly less than that
of isografts in subgroup a; by contrast, no difference
was seen in the ratio of viable chondrocytes of the iso-
grafts undergoing cryopreservation for less than 6
months between subgroups a and b (Fig 3). Tracheal
isografts undergoing cryopreservation for less than 3
months in subgroup c had some viable cartilage islands
and also showed new chondrocytes in the adventitial
area (Fig 2, A and B). In contrast, the isografts under-
going cryopreservation for more than 6 months in sub-
group c showed an exacerbating trend according to the
length of the cryopreservation period and also had non-
viable chondrocyte nuclei in the lacunae. Above all, the
isografts undergoing cryopreservation for 6 months in
subgroup c showed a significantly worse ratio than
those undergoing the same preservation in subgroup b
(P =.02) (Table III). 
Discussion
We previously studied graft viability,9,10 rejection
reaction,5 minimal immunosuppression,6,11 and recon-
Fig 1. The epithelial score (mean ± standard deviation of the
mean) of tracheal isografts in subgroup a (open circles) and
of those in subgroup b (closed circles). Zero months’ cryo-
preservation designates the fresh trachea isografts. The
epithelial score in subgroup b was significantly better than
that in subgroup a in the isografts cryopreserved for 0.25
month (1 week) (P = .02).
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struction range7-9,12,13 in tracheal allotransplantation for
eventual clinical use in human beings. As a result, graft
viability was maintained by omental wrapping.9,10 The
epithelial morphology of the graft was closely associat-
ed with the rejection reaction.5 Minimal immuno-
suppression using a minimal dose of cyclosporin A
(Sandoz Pharma AG, Basel, Switzerland) (INN:
ciclosporin) or a short course of mizoribine (Bredinin;
Asahikasei Co, Ltd, Tokyo, Japan) was feasible.6,11
Extensive airway reconstruction involving the carina
was feasible with the use of a long-segment graft by the
application of basic fibroblast growth factor or a short-
segment graft under conditions of anastomotic tension
of less than 1.0 kg.7,8,12,13 The preservation of the tra-
chea, however, is still unsolved. We therefore studied
the long period of cryopreservation for viable tracheal
isografts.
Generally, cryopreservation of biomaterials is initiat-
ed by a slow-freezing system, which is composed of a
computer-controlled unit that freezes at a rate of 1°C to
5°C per minute until reaching –80°C to –100°C.14 The
Fig 2. Micrographs of tracheal isografts 3 months after transplantation. A, Group 4c. Normal mucociliary epithe-
lium is recognized extensively. The cartilage has viable chondrocyte nuclei and cytoplasm filled with viscous liq-
uid in the lacunae. B, Group 6c. Mucociliary epithelium with goblet-like cells is often recognized. The cartilage
has viable chondrocyte nuclei but the amount of viscous liquid has decreased in the cytoplasm. New chondro-
cytes are seen in the adventitial area. (Hematoxylin and eosin; original magnification, · 400.)
Fig 3. The ratio of viable chondrocytes (mean ± standard
deviation of the mean) of tracheal isografts in subgroup a
(open circles) and of those in subgroup b (closed circles).
Zero months’ cryopreservation designates the fresh tracheal
isografts. The viable chondrocyte ratio in subgroup b was sig-
nificantly worse than that in subgroup a in the isografts cry-
opreserved for 0, 9, and 12 months (P = .04, .01, and .01,
respectively).
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Bicell biofreezing vessel stored in a deep freezer at
–80°C has almost the same ability as slow-freezing
instruments when compared with computer-controlled
units. This vessel potentially prevents deterioration of
cell viability subsequent to the transient heat release
that occurs during crystallizing.15 Moreover, this vessel
is inexpensive and does not require a high running cost.
Cryopreservation with this vessel is thus considered to
be potentially acceptable at many institutions, and we
decided to use this vessel in our study.
Several studies on the effects of cryopreservation on
the trachea have been conducted. Deschamps and col-
leagues1 demonstrated that the gross anatomy of tra-
cheal autografts was maintained after cryopreservation
for 1 week, but a microscopic examination was not nec-
essarily done. Cryopreserved autografts showed nor-
mal epithelium, but the cartilage was abnormal as char-
acterized by a loss of chondrocyte nuclei in the
lacunae. In contrast, Yokomise and associates2 reported
that a 1-month cryopreservation did not affect the mor-
phology of either the epithelium or the cartilage. Some
differences exist in the cryopreserving methods, cryo-
preservation periods, and cryoprotective agents be-
tween both of these studies. Theoretically, the former
study must show better preservation of cartilage than
the latter study because of the use of a computer-con-
trolled freezing system, the cryopreservation system
using liquid nitrogen (–196°C), and the shorter-term
cryopreservation. In fact, the latter study, in which a
simple cryopreservation was performed, showed a bet-
ter preserved cartilage. Cryoprotectants using trehalose
and DMSO potentially played an important role in the
viability of the cartilage in the latter study. However,
the results of their study are still open to question
because no fine evaluation for cartilage was performed.
Therefore the synergistic effect of these cryoprotec-
tants still remains obscure. In this study, we used
DMSO alone as a cryoprotective agent in the same way
Table III. Viable chondrocyte ratio of tracheal isografts
Cryopreservation period (mo)
Treatment after thawing 1 3 6 12
Absent 0.622 ± 0.113* (group 4a) 0.622 ± 0.093* (group 6a) 0.545 ± 0.054‡ (group 7a) 0.405 ± 0.093‡ (group 9a)
Heterotopic 0.612 ± 0.128* (group 4b) 0.597 ± 0.085* (group 6b) 0.475 ± 0.103‡ (group 7b) 0.190 ± 0.114 (group 9b)
transplantation 
for 1 mo
Heterotopic 0.629 ± 0.170*† (group 4c) 0.544 ± 0.070*† (group 6c) 0.323 ± 0.054* (group 7c) 0.181 ± 0.068 (group 9c)
transplantation 
for 3 mo
*The viable chondrocyte ratio in each group was significantly better than that in the 12-month cryopreservation group at the same treatment course (group 4a vs 9a,
P = .04; group 6a vs 9a, P = .01; group 4b vs 9b, P = .002; group 6b vs 9b, P = .0001; group 4c vs 9c, P = .003; group 6c vs 9c, P = .0006; group 7c vs 9c, P = .01.
†The viable chondrocyte ratio in each group was significantly better than that in the 6-month cryopreservation group at the same treatment course (group 4c vs 7c,
P = .004; group 6c vs 7c, P = .0004).
‡The viable chrondrocyte ratio in each treatment group was significantly better than that in the 3-month transplantation group at the same cryopreservation period
(group 7a vs 7c, P = .0001; group 7b vs 7c, P = .02; group 9a vs 9c, P = .005).
Table II. Epithelial score of tracheal isografts
Cryopreservation period (mo) 
Treatment after thawing 1 3 6 12
Absent 1.055 ± 0.357* (group 4a) 1.283 ± 0.422*† (group 6a) 0.767 ± 0.216 (group 7a) 0.550 ± 0.302 (group 9a)
Heterotopic 1.300 ± 0.276* (group 4b) 1.433 ± 0.339* (group 6b) 1.267 ± 0.826 (group 7b) 0.467 ± 0.528 (group 9b)
transplantation 
for 1 mo
Heterotopic 1.750 ± 1.253*† (group 4c) 1.700 ± 0.494*† (group 6c) 0.250 ± 0.418 (group 7c) 0.183 ± 0.133 (group 9c)
transplantation 
for 3 mo
*The epithelial score in each group was significantly better than that in the 12-month cryopreservation group at the same treatment course (group 4a vs 9a, P = .04;
group 6a vs 9a, P = .01; group 4b vs 9b, P = .01; group 6b vs 9b, P = .01; group 4c vs 9c, P = .03; group 6c vs 9c, P = .0008).
†The epithelial score in each group was significantly better than that in the 6-month cryopreservation group at the same treatment course (group 6a vs 7a, P = .03;
group 4c vs 7c, P = .03; group 6c vs 7c, P = .003).
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as Deschamps and colleagues1 because it is the most
standard and well-established method.3,4,14,16,17
Our careful evaluation of the histologic morphology
of the tracheal isografts suggested a prolonged period
of cryopreservation to have a degenerative effect on
both the epithelium and the cartilage. The cartilage
showed more degeneration than the epithelium, as
characterized by the viable chondrocyte ratio and the
epithelial score of isografts treated with a 1-month
transplantation after cryopreservation for more than 9
months. This may be one of the reasons that the cryo-
protectant did not penetrate deeply into the cartilage.
Cryopreserved tracheal isografts that are transplanted
heterotopically are considered to require a long period
to restore their structural integrity owing to damage
during cryopreservation. We assessed the tracheal
structure 3 months and 1 month after syngeneic trans-
plantation in view of previously investigated canine tra-
cheal transplantation models.9,10 The prolonged period
of transplantation thus showed the permissible period
of cryopreservation for tracheal isografts. The mor-
phology of the epithelium or cartilage in the isografts
undergoing a cryopreservation period of less than 3
months was improved or maintained, respectively. In
contrast, the prolonged period of transplantation
showed deterioration in the morphology in both the
epithelium and cartilage in isografts undergoing cryo-
preservation for more than 6 months. Essentially, the
prolonged period of transplantation should improve the
wound healing of the graft in the tracheal autotrans-
plantation model.7-10 Therefore a cryopreservation peri-
od of more than 6 months definitely negatively influ-
ences the graft morphology in this system.
This limitation of the cryopreservation period is
mainly due to the temperature of cryopreservation. The
cellular membrane is subject to impairment during
long-term cryopreservation at more than –130°C
because that temperature tends to cause intracellular
recrystallization.18 Therefore liquid nitrogen (–196°C)
is required as a future strategy for long-term cryo-
preservation, and using it would promise a longer peri-
od of cryopreservation. Other reasons for the limita-
tions of the cryopreservation period potentially include
the cold shock that occurs during the course of freezing
and thawing injury.19,20 In this experiment, the Bicell
device as the freezing instrument, DMSO as the cryo-
protectant, and RPMI-1640 and fetal calf serum as the
medium to keep osmotic pressure balance were used to
prevent cold shock. The cryopreserved isografts were
then thawed in the standard fashion to prevent any
intracellular recrystallization or unbalanced osmotic
pressure.20 Therefore such factors are not considered to
have a greater effect on the period of cryopreservation
than the temperature during cryopreservation.
In conclusion, cryopreservation for more than 6
months worsened the viability of both the epithelium
and cartilage of tracheal isografts according to the
length of the transplantation period, whereas cryo-
preservation for less than 3 months either improved
or maintained their viability. The permissible period
of cryopreservation in this simple system using the
Bicell device is thus considered to be 3 months.
Cryopreservation for 3 months at –80°C in this sys-
tem is considered to be acceptable in the clinical set-
ting of many institutions because of its low cost and
simplicity.
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